VALLEY FORGE, Pa., Nov 11, 2010 (BUSINESS WIRE) --
The Board of Directors of AmerisourceBergen Corporation (NYSE: ABC)
today increased the Company's quarterly dividend rate 25 percent to
$0.10 per common share from $0.08 per common share.
R. David Yost, AmerisourceBergen President & Chief Executive Officer,
said, "We are pleased that for the fifth consecutive year, we have
increased our dividend 25 percent or more, demonstrating our continued
confidence in delivering long-term shareholder value."
The quarterly dividend of $0.10 per common share will be payable
December 6, 2010, to stockholders of record at the close of business on
November 22, 2010.
About AmerisourceBergen
AmerisourceBergen is one of the world's largest pharmaceutical services
companies serving the United States, Canada and selected global markets.
Servicing both healthcare providers and pharmaceutical manufacturers in
the pharmaceutical supply channel, the Company provides drug
distribution and related services designed to reduce costs and improve
patient outcomes. AmerisourceBergen's service solutions range from
pharmacy automation and pharmaceutical packaging to reimbursement and
pharmaceutical consulting services. With $78 billion in annual revenue,
AmerisourceBergen is headquartered in Valley Forge, PA, and employs
approximately 10,000 people. AmerisourceBergen is ranked #24 on the
Fortune 500 list. For more information, go to www.amerisourcebergen.com.
Forward-Looking Statements
Certain of the statements contained in this press release are
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. These statements are based on management's current expectations
and are subject to uncertainty and change in circumstances. Among the
factors that could cause actual results to differ materially from those
projected, anticipated or implied are the following: changes in
pharmaceutical market growth rates; the loss of one or more key customer
or supplier relationships; changes in customer mix; customer
delinquencies, defaults or insolvencies; supplier defaults or
insolvencies; changes in pharmaceutical manufacturers' pricing and
distribution policies or practices; adverse resolution of any contract
or other dispute with customers or suppliers; federal and state
government enforcement initiatives to detect and prevent suspicious
orders of controlled substances and the diversion of controlled
substances; quitam litigation for alleged violations of
fraud and abuse laws and regulations and/or any other laws and
regulations governing the marketing, sale and purchase of pharmaceutical
products or any related litigation, including shareholder derivative
lawsuits; changes in U.S. legislation or regulatory action affecting
pharmaceutical product pricing or reimbursement policies, including
under Medicaid and Medicare; changes in regulatory or clinical medical
guidelines and/or labeling for the pharmaceutical products we
distribute, including certain anemia products; price inflation in
branded pharmaceuticals and price deflation in generics; greater or less
than anticipated benefit from launches of the generic versions of
previously patented pharmaceutical products; significant breakdown or
interruption of our information technology systems; our inability to
implement an enterprise resource planning (ERP) system to handle
business and financial processes and transactions (including processes
and transactions relating to our customers and suppliers) of
AmerisourceBergen Drug Corporation and our corporate operations without
functional problems, unanticipated delays and/or cost overruns; success
of integration, restructuring or systems initiatives; interest rate and
foreign currency exchange rate fluctuations; economic, business,
competitive and/or regulatory developments in Canada, the United Kingdom
and elsewhere outside of the United States, including potential changes
in Canadian provincial legislation affecting pharmaceutical product
pricing, dispensing or service fees and/or regulatory action by
provincial authorities in Canada to lower pharmaceutical product
pricing, dispensing or service fees; the impact of divestitures or the
acquisition of businesses that do not perform as we expect, are
difficult for us to integrate into our business operations or do not
adhere to our system of internal controls; our inability to successfully
complete any other transaction that we may wish to pursue from time to
time; changes in tax legislation or adverse resolution of challenges to
our tax positions; increased costs of maintaining, or reductions in our
ability to maintain, adequate liquidity and financing sources;
volatility and deterioration of the capital and credit markets; and
other economic, business, competitive, legal, tax, regulatory and/or
operational factors affecting our business generally. Certain additional
factors that management believes could cause actual outcomes and results
to differ materially from those described in forward-looking statements
are set forth (i) in Item 1A (Risk Factors) in the Company's Annual
Report on Form 10-K for this Fiscal Year Ended September 30, 2009 and
elsewhere in that report and (ii) in other reports filed by the Company
pursuant to the Securities Exchange Act of 1934.
SOURCE: AmerisourceBergen Corporation
AmerisourceBergen Corporation
Barbara Brungess, 610-727-7199
bbrungess@amerisourcebergen.com